Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole. This w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Furuno, Jon P., Tallman, Gregory B., Noble, Brie N., Bubalo, Joseph S., Forrest, Graeme N., Lewis, James S., Bienvenida, Ana F., Holmes, Courtney A., Weber, Bo R., McGregor, Jessina C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2018
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153813/
https://ncbi.nlm.nih.gov/pubmed/30012757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00893-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados